Overbought Stocks
BCAX appears in our Overbought Stocks screen, meaning it has experienced strong recent gains and may be trading at extended levels that could lead to short-term consolidation or pullback.
BICARA THERAPEUTICS INC (BCAX) Stock Price & Overview
NASDAQ:BCAX • US0554771032
Current stock price
24.01 USD
+0.08 (+0.33%)
At close:
24.01 USD
0 (0%)
After Hours:
The current stock price of BCAX is 24.01 USD. Today BCAX is up by 0.33%. In the past month the price increased by 27.78%. In the past year, price increased by 97.45%.
BCAX Key Statistics
52-Week Range7.8 - 24.25
Current BCAX stock price positioned within its 52-week range.
1-Month Range17.63 - 24.25
Current BCAX stock price positioned within its 1-month range.
- Market Cap
- 1.572B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.53
- Dividend Yield
- N/A
BCAX Stock Performance
Today
+0.33%
1 Week
+13.68%
1 Month
+27.78%
3 Months
+43.34%
Longer-term
6 Months +31.56%
1 Year +97.45%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
BCAX Stock Chart
BCAX Stock Screens
BCAX currently appears in the following ChartMill screener lists.
BCAX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to BCAX. When comparing the yearly performance of all stocks, BCAX is one of the better performing stocks in the market, outperforming 92.39% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
BCAX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BCAX. While BCAX has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BCAX Earnings
Next Earnings DateMay 11, 2026
Last Earnings DateMar 30, 2026
PeriodQ4 / 2025
EPS Reported-$0.68
Revenue Reported
EPS Surprise 0.66%
Revenue Surprise %
BCAX Forecast & Estimates
20 analysts have analysed BCAX and the average price target is 31.11 USD. This implies a price increase of 29.57% is expected in the next year compared to the current price of 24.01.
Analysts
Analysts82
Price Target31.11 (29.57%)
EPS Next Y-7.1%
Revenue Next YearN/A
BCAX Groups
Sector & Classification
BCAX Financial Highlights
Over the last trailing twelve months BCAX reported a non-GAAP Earnings per Share(EPS) of -2.53. The EPS increased by 37.64% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-137.95M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.01% | ||
| ROE | -34.36% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-74.36%
Sales Q2Q%N/A
EPS 1Y (TTM)37.64%
Revenue 1Y (TTM)N/A
BCAX Ownership
Ownership
Inst Owners83.49%
Shares65.47M
Float55.54M
Ins Owners1.26%
Short Float %17.36%
Short Ratio17.11
BCAX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.05 | 369.653B | ||
| AMGN | AMGEN INC | 15.56 | 188.346B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 171.971B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.65 | 110.812B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.01 | 78.867B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.37 | 42.456B | ||
| INSM | INSMED INC | N/A | 30.821B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.581B | ||
| NTRA | NATERA INC | N/A | 27.795B | ||
| BIIB | BIOGEN INC | 11 | 25.833B | ||
| UTHR | UNITED THERAPEUTICS CORP | 20.13 | 25.444B | ||
| MRNA | MODERNA INC | N/A | 21.686B | ||
| INCY | INCYTE CORP | 12.64 | 18.97B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BCAX
Company Profile
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company is headquartered in Boston, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2024-09-13. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
Company Info
IPO: 2024-09-13
BICARA THERAPEUTICS INC
116 Huntington Avenue Suite 703
Boston MASSACHUSETTS US
Employees: 103
Phone: 16174684219
BICARA THERAPEUTICS INC / BCAX FAQ
What does BICARA THERAPEUTICS INC do?
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company is headquartered in Boston, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2024-09-13. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
What is the stock price of BICARA THERAPEUTICS INC today?
The current stock price of BCAX is 24.01 USD. The price increased by 0.33% in the last trading session.
What is the dividend status of BICARA THERAPEUTICS INC?
BCAX does not pay a dividend.
What is the ChartMill technical and fundamental rating of BCAX stock?
BCAX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is BICARA THERAPEUTICS INC (BCAX) stock traded?
BCAX stock is listed on the Nasdaq exchange.
How is the valuation of BICARA THERAPEUTICS INC (BCAX) based on its PE ratio?
BICARA THERAPEUTICS INC (BCAX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.53).
What is the market capitalization of BCAX stock?
BICARA THERAPEUTICS INC (BCAX) has a market capitalization of 1.57B USD. This makes BCAX a Small Cap stock.